Evaluating the efficacy of allopurinol for the treatment of cutaneous leishmaniasis
This study was performed in Corte de Pedra, an area of L. braziliensis braziliensis transmission located 240 km southeast of Salvador, the capital of the state of Bahia in Brazil. This open controlled trial included 34 patients, aged 12 to 45 years, with leishmania-positive skin test and a maximum o...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
D'Oliveira, Argemiro - md [verfasserIn] Machado, Paulo Roberto L. - md [verfasserIn] Carvalho, Edgar M. - md, phd [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|
| Erschienen: |
Oxford, UK: Blackwell Publishing Ltd ; 1997 |
|---|
| Umfang: |
Online-Ressource |
|---|
| Reproduktion: |
2008 ; Blackwell Publishing Journal Backfiles 1879-2005 |
|---|---|
| Übergeordnetes Werk: |
In: International journal of dermatology - Oxford [u.a.] : Wiley-Blackwell, 1970, 36(1997), 12, Seite 0 |
| Übergeordnetes Werk: |
volume:36 ; year:1997 ; number:12 ; pages:0 |
| Links: |
|---|
| DOI / URN: |
10.1046/j.1365-4362.1997.00308.x |
|---|
| Katalog-ID: |
NLEJ242732313 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLEJ242732313 | ||
| 003 | DE-627 | ||
| 005 | 20230505221457.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 120427s1997 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.1046/j.1365-4362.1997.00308.x |2 doi | |
| 035 | |a (DE-627)NLEJ242732313 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 100 | 1 | |a D'Oliveira, Argemiro |c md |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Evaluating the efficacy of allopurinol for the treatment of cutaneous leishmaniasis |
| 264 | 1 | |a Oxford, UK |b Blackwell Publishing Ltd |c 1997 | |
| 300 | |a Online-Ressource | ||
| 336 | |a nicht spezifiziert |b zzz |2 rdacontent | ||
| 337 | |a nicht spezifiziert |b z |2 rdamedia | ||
| 338 | |a nicht spezifiziert |b zu |2 rdacarrier | ||
| 520 | |a This study was performed in Corte de Pedra, an area of L. braziliensis braziliensis transmission located 240 km southeast of Salvador, the capital of the state of Bahia in Brazil. This open controlled trial included 34 patients, aged 12 to 45 years, with leishmania-positive skin test and a maximum of three ulcerated lesions (with a minimum lesion diameter of 10 mm and a maximum diameter of 50 mm) who had received no previous treatment. Exclusion criteria included chronic disease, use of other drugs, history of allergy to allopurinol, pregnancy, breast feeding, or forms of leishmaniasis other than cutaneous. Informed consent was obtained from all subjects after the nature of the procedures had been fully explained to them.Randomly selected patients received 20 mg/kg of allopurinol orally, three times a day, or 10 mg/kg of intravenous antimoniate of meglumine, once a day. Both patient groups used the drugs for a period of 20 days. A clinical history was collected and a physical examination was performed on all patients before initiating the treatment. Lesions were photographed and biopsied, and the tissue was used for histopathologic study and inoculation in hamsters and appropriate culture media. Patients were re-examined on days 10 and 20 and at monthly intervals for 1 year following the beginning of treatment. Blood samples for serologic and biochemical analysis (measurements of serum uric acid, urea, crsatinine, and transaminases) were collected at days 0, 10, and 22 following the beginning of treatment.The definition of therapeutic failure included incompletion of the treatment protocol, use of a treatment different from the protocol, lesions not healed 3 months after the beginning of treatment, or relapse or development of new cutaneous or mucosal lesions caused by leishmaniasis within 1 year of treatment.The exact Fischer test was used to compare the treatment results between the two patient groups. Student's t-test was used to compare the age of the patients and the duration of the illness. The Mann-Whitney test was used to compare the diameter of the lesions at day 0 and 3 months after treatment completion in the two groups, and the Kruskal-Wallis test was used to compare the number of lesions per patient and their localization. | ||
| 533 | |d 2008 |f Blackwell Publishing Journal Backfiles 1879-2005 |7 |2008|||||||||| | ||
| 700 | 1 | |a Machado, Paulo Roberto L. |c md |e verfasserin |4 aut | |
| 700 | 1 | |a Carvalho, Edgar M. |c md, phd |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t International journal of dermatology |d Oxford [u.a.] : Wiley-Blackwell, 1970 |g 36(1997), 12, Seite 0 |h Online-Ressource |w (DE-627)NLEJ243927347 |w (DE-600)2020365-2 |x 1365-4632 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:1997 |g number:12 |g pages:0 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1046/j.1365-4362.1997.00308.x |q text/html |x Verlag |z Deutschlandweit zugänglich |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a ZDB-1-DJB | ||
| 912 | |a GBV_NL_ARTICLE | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 1997 |e 12 |h 0 | ||
| author_variant |
a d ad p r l m prl prlm e m c em emc |
|---|---|
| matchkey_str |
article:13654632:1997----::vlaighefccoalprnloteramnoct |
| hierarchy_sort_str |
1997 |
| publishDate |
1997 |
| allfields |
10.1046/j.1365-4362.1997.00308.x doi (DE-627)NLEJ242732313 DE-627 ger DE-627 rakwb D'Oliveira, Argemiro md verfasserin aut Evaluating the efficacy of allopurinol for the treatment of cutaneous leishmaniasis Oxford, UK Blackwell Publishing Ltd 1997 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier This study was performed in Corte de Pedra, an area of L. braziliensis braziliensis transmission located 240 km southeast of Salvador, the capital of the state of Bahia in Brazil. This open controlled trial included 34 patients, aged 12 to 45 years, with leishmania-positive skin test and a maximum of three ulcerated lesions (with a minimum lesion diameter of 10 mm and a maximum diameter of 50 mm) who had received no previous treatment. Exclusion criteria included chronic disease, use of other drugs, history of allergy to allopurinol, pregnancy, breast feeding, or forms of leishmaniasis other than cutaneous. Informed consent was obtained from all subjects after the nature of the procedures had been fully explained to them.Randomly selected patients received 20 mg/kg of allopurinol orally, three times a day, or 10 mg/kg of intravenous antimoniate of meglumine, once a day. Both patient groups used the drugs for a period of 20 days. A clinical history was collected and a physical examination was performed on all patients before initiating the treatment. Lesions were photographed and biopsied, and the tissue was used for histopathologic study and inoculation in hamsters and appropriate culture media. Patients were re-examined on days 10 and 20 and at monthly intervals for 1 year following the beginning of treatment. Blood samples for serologic and biochemical analysis (measurements of serum uric acid, urea, crsatinine, and transaminases) were collected at days 0, 10, and 22 following the beginning of treatment.The definition of therapeutic failure included incompletion of the treatment protocol, use of a treatment different from the protocol, lesions not healed 3 months after the beginning of treatment, or relapse or development of new cutaneous or mucosal lesions caused by leishmaniasis within 1 year of treatment.The exact Fischer test was used to compare the treatment results between the two patient groups. Student's t-test was used to compare the age of the patients and the duration of the illness. The Mann-Whitney test was used to compare the diameter of the lesions at day 0 and 3 months after treatment completion in the two groups, and the Kruskal-Wallis test was used to compare the number of lesions per patient and their localization. 2008 Blackwell Publishing Journal Backfiles 1879-2005 |2008|||||||||| Machado, Paulo Roberto L. md verfasserin aut Carvalho, Edgar M. md, phd verfasserin aut In International journal of dermatology Oxford [u.a.] : Wiley-Blackwell, 1970 36(1997), 12, Seite 0 Online-Ressource (DE-627)NLEJ243927347 (DE-600)2020365-2 1365-4632 nnns volume:36 year:1997 number:12 pages:0 http://dx.doi.org/10.1046/j.1365-4362.1997.00308.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 36 1997 12 0 |
| spelling |
10.1046/j.1365-4362.1997.00308.x doi (DE-627)NLEJ242732313 DE-627 ger DE-627 rakwb D'Oliveira, Argemiro md verfasserin aut Evaluating the efficacy of allopurinol for the treatment of cutaneous leishmaniasis Oxford, UK Blackwell Publishing Ltd 1997 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier This study was performed in Corte de Pedra, an area of L. braziliensis braziliensis transmission located 240 km southeast of Salvador, the capital of the state of Bahia in Brazil. This open controlled trial included 34 patients, aged 12 to 45 years, with leishmania-positive skin test and a maximum of three ulcerated lesions (with a minimum lesion diameter of 10 mm and a maximum diameter of 50 mm) who had received no previous treatment. Exclusion criteria included chronic disease, use of other drugs, history of allergy to allopurinol, pregnancy, breast feeding, or forms of leishmaniasis other than cutaneous. Informed consent was obtained from all subjects after the nature of the procedures had been fully explained to them.Randomly selected patients received 20 mg/kg of allopurinol orally, three times a day, or 10 mg/kg of intravenous antimoniate of meglumine, once a day. Both patient groups used the drugs for a period of 20 days. A clinical history was collected and a physical examination was performed on all patients before initiating the treatment. Lesions were photographed and biopsied, and the tissue was used for histopathologic study and inoculation in hamsters and appropriate culture media. Patients were re-examined on days 10 and 20 and at monthly intervals for 1 year following the beginning of treatment. Blood samples for serologic and biochemical analysis (measurements of serum uric acid, urea, crsatinine, and transaminases) were collected at days 0, 10, and 22 following the beginning of treatment.The definition of therapeutic failure included incompletion of the treatment protocol, use of a treatment different from the protocol, lesions not healed 3 months after the beginning of treatment, or relapse or development of new cutaneous or mucosal lesions caused by leishmaniasis within 1 year of treatment.The exact Fischer test was used to compare the treatment results between the two patient groups. Student's t-test was used to compare the age of the patients and the duration of the illness. The Mann-Whitney test was used to compare the diameter of the lesions at day 0 and 3 months after treatment completion in the two groups, and the Kruskal-Wallis test was used to compare the number of lesions per patient and their localization. 2008 Blackwell Publishing Journal Backfiles 1879-2005 |2008|||||||||| Machado, Paulo Roberto L. md verfasserin aut Carvalho, Edgar M. md, phd verfasserin aut In International journal of dermatology Oxford [u.a.] : Wiley-Blackwell, 1970 36(1997), 12, Seite 0 Online-Ressource (DE-627)NLEJ243927347 (DE-600)2020365-2 1365-4632 nnns volume:36 year:1997 number:12 pages:0 http://dx.doi.org/10.1046/j.1365-4362.1997.00308.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 36 1997 12 0 |
| allfields_unstemmed |
10.1046/j.1365-4362.1997.00308.x doi (DE-627)NLEJ242732313 DE-627 ger DE-627 rakwb D'Oliveira, Argemiro md verfasserin aut Evaluating the efficacy of allopurinol for the treatment of cutaneous leishmaniasis Oxford, UK Blackwell Publishing Ltd 1997 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier This study was performed in Corte de Pedra, an area of L. braziliensis braziliensis transmission located 240 km southeast of Salvador, the capital of the state of Bahia in Brazil. This open controlled trial included 34 patients, aged 12 to 45 years, with leishmania-positive skin test and a maximum of three ulcerated lesions (with a minimum lesion diameter of 10 mm and a maximum diameter of 50 mm) who had received no previous treatment. Exclusion criteria included chronic disease, use of other drugs, history of allergy to allopurinol, pregnancy, breast feeding, or forms of leishmaniasis other than cutaneous. Informed consent was obtained from all subjects after the nature of the procedures had been fully explained to them.Randomly selected patients received 20 mg/kg of allopurinol orally, three times a day, or 10 mg/kg of intravenous antimoniate of meglumine, once a day. Both patient groups used the drugs for a period of 20 days. A clinical history was collected and a physical examination was performed on all patients before initiating the treatment. Lesions were photographed and biopsied, and the tissue was used for histopathologic study and inoculation in hamsters and appropriate culture media. Patients were re-examined on days 10 and 20 and at monthly intervals for 1 year following the beginning of treatment. Blood samples for serologic and biochemical analysis (measurements of serum uric acid, urea, crsatinine, and transaminases) were collected at days 0, 10, and 22 following the beginning of treatment.The definition of therapeutic failure included incompletion of the treatment protocol, use of a treatment different from the protocol, lesions not healed 3 months after the beginning of treatment, or relapse or development of new cutaneous or mucosal lesions caused by leishmaniasis within 1 year of treatment.The exact Fischer test was used to compare the treatment results between the two patient groups. Student's t-test was used to compare the age of the patients and the duration of the illness. The Mann-Whitney test was used to compare the diameter of the lesions at day 0 and 3 months after treatment completion in the two groups, and the Kruskal-Wallis test was used to compare the number of lesions per patient and their localization. 2008 Blackwell Publishing Journal Backfiles 1879-2005 |2008|||||||||| Machado, Paulo Roberto L. md verfasserin aut Carvalho, Edgar M. md, phd verfasserin aut In International journal of dermatology Oxford [u.a.] : Wiley-Blackwell, 1970 36(1997), 12, Seite 0 Online-Ressource (DE-627)NLEJ243927347 (DE-600)2020365-2 1365-4632 nnns volume:36 year:1997 number:12 pages:0 http://dx.doi.org/10.1046/j.1365-4362.1997.00308.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 36 1997 12 0 |
| allfieldsGer |
10.1046/j.1365-4362.1997.00308.x doi (DE-627)NLEJ242732313 DE-627 ger DE-627 rakwb D'Oliveira, Argemiro md verfasserin aut Evaluating the efficacy of allopurinol for the treatment of cutaneous leishmaniasis Oxford, UK Blackwell Publishing Ltd 1997 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier This study was performed in Corte de Pedra, an area of L. braziliensis braziliensis transmission located 240 km southeast of Salvador, the capital of the state of Bahia in Brazil. This open controlled trial included 34 patients, aged 12 to 45 years, with leishmania-positive skin test and a maximum of three ulcerated lesions (with a minimum lesion diameter of 10 mm and a maximum diameter of 50 mm) who had received no previous treatment. Exclusion criteria included chronic disease, use of other drugs, history of allergy to allopurinol, pregnancy, breast feeding, or forms of leishmaniasis other than cutaneous. Informed consent was obtained from all subjects after the nature of the procedures had been fully explained to them.Randomly selected patients received 20 mg/kg of allopurinol orally, three times a day, or 10 mg/kg of intravenous antimoniate of meglumine, once a day. Both patient groups used the drugs for a period of 20 days. A clinical history was collected and a physical examination was performed on all patients before initiating the treatment. Lesions were photographed and biopsied, and the tissue was used for histopathologic study and inoculation in hamsters and appropriate culture media. Patients were re-examined on days 10 and 20 and at monthly intervals for 1 year following the beginning of treatment. Blood samples for serologic and biochemical analysis (measurements of serum uric acid, urea, crsatinine, and transaminases) were collected at days 0, 10, and 22 following the beginning of treatment.The definition of therapeutic failure included incompletion of the treatment protocol, use of a treatment different from the protocol, lesions not healed 3 months after the beginning of treatment, or relapse or development of new cutaneous or mucosal lesions caused by leishmaniasis within 1 year of treatment.The exact Fischer test was used to compare the treatment results between the two patient groups. Student's t-test was used to compare the age of the patients and the duration of the illness. The Mann-Whitney test was used to compare the diameter of the lesions at day 0 and 3 months after treatment completion in the two groups, and the Kruskal-Wallis test was used to compare the number of lesions per patient and their localization. 2008 Blackwell Publishing Journal Backfiles 1879-2005 |2008|||||||||| Machado, Paulo Roberto L. md verfasserin aut Carvalho, Edgar M. md, phd verfasserin aut In International journal of dermatology Oxford [u.a.] : Wiley-Blackwell, 1970 36(1997), 12, Seite 0 Online-Ressource (DE-627)NLEJ243927347 (DE-600)2020365-2 1365-4632 nnns volume:36 year:1997 number:12 pages:0 http://dx.doi.org/10.1046/j.1365-4362.1997.00308.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 36 1997 12 0 |
| allfieldsSound |
10.1046/j.1365-4362.1997.00308.x doi (DE-627)NLEJ242732313 DE-627 ger DE-627 rakwb D'Oliveira, Argemiro md verfasserin aut Evaluating the efficacy of allopurinol for the treatment of cutaneous leishmaniasis Oxford, UK Blackwell Publishing Ltd 1997 Online-Ressource nicht spezifiziert zzz rdacontent nicht spezifiziert z rdamedia nicht spezifiziert zu rdacarrier This study was performed in Corte de Pedra, an area of L. braziliensis braziliensis transmission located 240 km southeast of Salvador, the capital of the state of Bahia in Brazil. This open controlled trial included 34 patients, aged 12 to 45 years, with leishmania-positive skin test and a maximum of three ulcerated lesions (with a minimum lesion diameter of 10 mm and a maximum diameter of 50 mm) who had received no previous treatment. Exclusion criteria included chronic disease, use of other drugs, history of allergy to allopurinol, pregnancy, breast feeding, or forms of leishmaniasis other than cutaneous. Informed consent was obtained from all subjects after the nature of the procedures had been fully explained to them.Randomly selected patients received 20 mg/kg of allopurinol orally, three times a day, or 10 mg/kg of intravenous antimoniate of meglumine, once a day. Both patient groups used the drugs for a period of 20 days. A clinical history was collected and a physical examination was performed on all patients before initiating the treatment. Lesions were photographed and biopsied, and the tissue was used for histopathologic study and inoculation in hamsters and appropriate culture media. Patients were re-examined on days 10 and 20 and at monthly intervals for 1 year following the beginning of treatment. Blood samples for serologic and biochemical analysis (measurements of serum uric acid, urea, crsatinine, and transaminases) were collected at days 0, 10, and 22 following the beginning of treatment.The definition of therapeutic failure included incompletion of the treatment protocol, use of a treatment different from the protocol, lesions not healed 3 months after the beginning of treatment, or relapse or development of new cutaneous or mucosal lesions caused by leishmaniasis within 1 year of treatment.The exact Fischer test was used to compare the treatment results between the two patient groups. Student's t-test was used to compare the age of the patients and the duration of the illness. The Mann-Whitney test was used to compare the diameter of the lesions at day 0 and 3 months after treatment completion in the two groups, and the Kruskal-Wallis test was used to compare the number of lesions per patient and their localization. 2008 Blackwell Publishing Journal Backfiles 1879-2005 |2008|||||||||| Machado, Paulo Roberto L. md verfasserin aut Carvalho, Edgar M. md, phd verfasserin aut In International journal of dermatology Oxford [u.a.] : Wiley-Blackwell, 1970 36(1997), 12, Seite 0 Online-Ressource (DE-627)NLEJ243927347 (DE-600)2020365-2 1365-4632 nnns volume:36 year:1997 number:12 pages:0 http://dx.doi.org/10.1046/j.1365-4362.1997.00308.x text/html Verlag Deutschlandweit zugänglich Volltext GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE AR 36 1997 12 0 |
| source |
In International journal of dermatology 36(1997), 12, Seite 0 volume:36 year:1997 number:12 pages:0 |
| sourceStr |
In International journal of dermatology 36(1997), 12, Seite 0 volume:36 year:1997 number:12 pages:0 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| isfreeaccess_bool |
false |
| container_title |
International journal of dermatology |
| authorswithroles_txt_mv |
D'Oliveira, Argemiro @@aut@@ Machado, Paulo Roberto L. @@aut@@ Carvalho, Edgar M. @@aut@@ |
| publishDateDaySort_date |
1997-01-01T00:00:00Z |
| hierarchy_top_id |
NLEJ243927347 |
| id |
NLEJ242732313 |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242732313</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505221457.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s1997 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1046/j.1365-4362.1997.00308.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242732313</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">D'Oliveira, Argemiro</subfield><subfield code="c">md</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Evaluating the efficacy of allopurinol for the treatment of cutaneous leishmaniasis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Publishing Ltd</subfield><subfield code="c">1997</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This study was performed in Corte de Pedra, an area of L. braziliensis braziliensis transmission located 240 km southeast of Salvador, the capital of the state of Bahia in Brazil. This open controlled trial included 34 patients, aged 12 to 45 years, with leishmania-positive skin test and a maximum of three ulcerated lesions (with a minimum lesion diameter of 10 mm and a maximum diameter of 50 mm) who had received no previous treatment. Exclusion criteria included chronic disease, use of other drugs, history of allergy to allopurinol, pregnancy, breast feeding, or forms of leishmaniasis other than cutaneous. Informed consent was obtained from all subjects after the nature of the procedures had been fully explained to them.Randomly selected patients received 20 mg/kg of allopurinol orally, three times a day, or 10 mg/kg of intravenous antimoniate of meglumine, once a day. Both patient groups used the drugs for a period of 20 days. A clinical history was collected and a physical examination was performed on all patients before initiating the treatment. Lesions were photographed and biopsied, and the tissue was used for histopathologic study and inoculation in hamsters and appropriate culture media. Patients were re-examined on days 10 and 20 and at monthly intervals for 1 year following the beginning of treatment. Blood samples for serologic and biochemical analysis (measurements of serum uric acid, urea, crsatinine, and transaminases) were collected at days 0, 10, and 22 following the beginning of treatment.The definition of therapeutic failure included incompletion of the treatment protocol, use of a treatment different from the protocol, lesions not healed 3 months after the beginning of treatment, or relapse or development of new cutaneous or mucosal lesions caused by leishmaniasis within 1 year of treatment.The exact Fischer test was used to compare the treatment results between the two patient groups. Student's t-test was used to compare the age of the patients and the duration of the illness. The Mann-Whitney test was used to compare the diameter of the lesions at day 0 and 3 months after treatment completion in the two groups, and the Kruskal-Wallis test was used to compare the number of lesions per patient and their localization.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2008</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2008||||||||||</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Machado, Paulo Roberto L.</subfield><subfield code="c">md</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Carvalho, Edgar M.</subfield><subfield code="c">md, phd</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">International journal of dermatology</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1970</subfield><subfield code="g">36(1997), 12, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243927347</subfield><subfield code="w">(DE-600)2020365-2</subfield><subfield code="x">1365-4632</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:36</subfield><subfield code="g">year:1997</subfield><subfield code="g">number:12</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1046/j.1365-4362.1997.00308.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">36</subfield><subfield code="j">1997</subfield><subfield code="e">12</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| series2 |
Blackwell Publishing Journal Backfiles 1879-2005 |
| author |
D'Oliveira, Argemiro md |
| spellingShingle |
D'Oliveira, Argemiro md Evaluating the efficacy of allopurinol for the treatment of cutaneous leishmaniasis |
| authorStr |
D'Oliveira, Argemiro md |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)NLEJ243927347 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut |
| collection |
NL |
| publishPlace |
Oxford, UK |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
1365-4632 |
| topic_title |
Evaluating the efficacy of allopurinol for the treatment of cutaneous leishmaniasis |
| publisher |
Blackwell Publishing Ltd |
| publisherStr |
Blackwell Publishing Ltd |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
zu |
| hierarchy_parent_title |
International journal of dermatology |
| hierarchy_parent_id |
NLEJ243927347 |
| hierarchy_top_title |
International journal of dermatology |
| isfreeaccess_txt |
false |
| familylinks_str_mv |
(DE-627)NLEJ243927347 (DE-600)2020365-2 |
| title |
Evaluating the efficacy of allopurinol for the treatment of cutaneous leishmaniasis |
| ctrlnum |
(DE-627)NLEJ242732313 |
| title_full |
Evaluating the efficacy of allopurinol for the treatment of cutaneous leishmaniasis |
| author_sort |
D'Oliveira, Argemiro md |
| journal |
International journal of dermatology |
| journalStr |
International journal of dermatology |
| isOA_bool |
false |
| recordtype |
marc |
| publishDateSort |
1997 |
| contenttype_str_mv |
zzz |
| container_start_page |
0 |
| author_browse |
D'Oliveira, Argemiro Machado, Paulo Roberto L. Carvalho, Edgar M. |
| container_volume |
36 |
| physical |
Online-Ressource |
| format_se |
Elektronische Aufsätze |
| author-letter |
D'Oliveira, Argemiro |
| doi_str_mv |
10.1046/j.1365-4362.1997.00308.x |
| author2-role |
verfasserin |
| title_sort |
evaluating the efficacy of allopurinol for the treatment of cutaneous leishmaniasis |
| title_auth |
Evaluating the efficacy of allopurinol for the treatment of cutaneous leishmaniasis |
| abstract |
This study was performed in Corte de Pedra, an area of L. braziliensis braziliensis transmission located 240 km southeast of Salvador, the capital of the state of Bahia in Brazil. This open controlled trial included 34 patients, aged 12 to 45 years, with leishmania-positive skin test and a maximum of three ulcerated lesions (with a minimum lesion diameter of 10 mm and a maximum diameter of 50 mm) who had received no previous treatment. Exclusion criteria included chronic disease, use of other drugs, history of allergy to allopurinol, pregnancy, breast feeding, or forms of leishmaniasis other than cutaneous. Informed consent was obtained from all subjects after the nature of the procedures had been fully explained to them.Randomly selected patients received 20 mg/kg of allopurinol orally, three times a day, or 10 mg/kg of intravenous antimoniate of meglumine, once a day. Both patient groups used the drugs for a period of 20 days. A clinical history was collected and a physical examination was performed on all patients before initiating the treatment. Lesions were photographed and biopsied, and the tissue was used for histopathologic study and inoculation in hamsters and appropriate culture media. Patients were re-examined on days 10 and 20 and at monthly intervals for 1 year following the beginning of treatment. Blood samples for serologic and biochemical analysis (measurements of serum uric acid, urea, crsatinine, and transaminases) were collected at days 0, 10, and 22 following the beginning of treatment.The definition of therapeutic failure included incompletion of the treatment protocol, use of a treatment different from the protocol, lesions not healed 3 months after the beginning of treatment, or relapse or development of new cutaneous or mucosal lesions caused by leishmaniasis within 1 year of treatment.The exact Fischer test was used to compare the treatment results between the two patient groups. Student's t-test was used to compare the age of the patients and the duration of the illness. The Mann-Whitney test was used to compare the diameter of the lesions at day 0 and 3 months after treatment completion in the two groups, and the Kruskal-Wallis test was used to compare the number of lesions per patient and their localization. |
| abstractGer |
This study was performed in Corte de Pedra, an area of L. braziliensis braziliensis transmission located 240 km southeast of Salvador, the capital of the state of Bahia in Brazil. This open controlled trial included 34 patients, aged 12 to 45 years, with leishmania-positive skin test and a maximum of three ulcerated lesions (with a minimum lesion diameter of 10 mm and a maximum diameter of 50 mm) who had received no previous treatment. Exclusion criteria included chronic disease, use of other drugs, history of allergy to allopurinol, pregnancy, breast feeding, or forms of leishmaniasis other than cutaneous. Informed consent was obtained from all subjects after the nature of the procedures had been fully explained to them.Randomly selected patients received 20 mg/kg of allopurinol orally, three times a day, or 10 mg/kg of intravenous antimoniate of meglumine, once a day. Both patient groups used the drugs for a period of 20 days. A clinical history was collected and a physical examination was performed on all patients before initiating the treatment. Lesions were photographed and biopsied, and the tissue was used for histopathologic study and inoculation in hamsters and appropriate culture media. Patients were re-examined on days 10 and 20 and at monthly intervals for 1 year following the beginning of treatment. Blood samples for serologic and biochemical analysis (measurements of serum uric acid, urea, crsatinine, and transaminases) were collected at days 0, 10, and 22 following the beginning of treatment.The definition of therapeutic failure included incompletion of the treatment protocol, use of a treatment different from the protocol, lesions not healed 3 months after the beginning of treatment, or relapse or development of new cutaneous or mucosal lesions caused by leishmaniasis within 1 year of treatment.The exact Fischer test was used to compare the treatment results between the two patient groups. Student's t-test was used to compare the age of the patients and the duration of the illness. The Mann-Whitney test was used to compare the diameter of the lesions at day 0 and 3 months after treatment completion in the two groups, and the Kruskal-Wallis test was used to compare the number of lesions per patient and their localization. |
| abstract_unstemmed |
This study was performed in Corte de Pedra, an area of L. braziliensis braziliensis transmission located 240 km southeast of Salvador, the capital of the state of Bahia in Brazil. This open controlled trial included 34 patients, aged 12 to 45 years, with leishmania-positive skin test and a maximum of three ulcerated lesions (with a minimum lesion diameter of 10 mm and a maximum diameter of 50 mm) who had received no previous treatment. Exclusion criteria included chronic disease, use of other drugs, history of allergy to allopurinol, pregnancy, breast feeding, or forms of leishmaniasis other than cutaneous. Informed consent was obtained from all subjects after the nature of the procedures had been fully explained to them.Randomly selected patients received 20 mg/kg of allopurinol orally, three times a day, or 10 mg/kg of intravenous antimoniate of meglumine, once a day. Both patient groups used the drugs for a period of 20 days. A clinical history was collected and a physical examination was performed on all patients before initiating the treatment. Lesions were photographed and biopsied, and the tissue was used for histopathologic study and inoculation in hamsters and appropriate culture media. Patients were re-examined on days 10 and 20 and at monthly intervals for 1 year following the beginning of treatment. Blood samples for serologic and biochemical analysis (measurements of serum uric acid, urea, crsatinine, and transaminases) were collected at days 0, 10, and 22 following the beginning of treatment.The definition of therapeutic failure included incompletion of the treatment protocol, use of a treatment different from the protocol, lesions not healed 3 months after the beginning of treatment, or relapse or development of new cutaneous or mucosal lesions caused by leishmaniasis within 1 year of treatment.The exact Fischer test was used to compare the treatment results between the two patient groups. Student's t-test was used to compare the age of the patients and the duration of the illness. The Mann-Whitney test was used to compare the diameter of the lesions at day 0 and 3 months after treatment completion in the two groups, and the Kruskal-Wallis test was used to compare the number of lesions per patient and their localization. |
| collection_details |
GBV_USEFLAG_U ZDB-1-DJB GBV_NL_ARTICLE |
| container_issue |
12 |
| title_short |
Evaluating the efficacy of allopurinol for the treatment of cutaneous leishmaniasis |
| url |
http://dx.doi.org/10.1046/j.1365-4362.1997.00308.x |
| remote_bool |
true |
| author2 |
Machado, Paulo Roberto L. md Carvalho, Edgar M. md, phd |
| author2Str |
Machado, Paulo Roberto L. md Carvalho, Edgar M. md, phd |
| ppnlink |
NLEJ243927347 |
| mediatype_str_mv |
z |
| isOA_txt |
false |
| hochschulschrift_bool |
false |
| doi_str |
10.1046/j.1365-4362.1997.00308.x |
| up_date |
2024-07-06T03:00:18.256Z |
| _version_ |
1803796944785506304 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">NLEJ242732313</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230505221457.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">120427s1997 xx |||||o 00| ||und c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1046/j.1365-4362.1997.00308.x</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)NLEJ242732313</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">D'Oliveira, Argemiro</subfield><subfield code="c">md</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Evaluating the efficacy of allopurinol for the treatment of cutaneous leishmaniasis</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Oxford, UK</subfield><subfield code="b">Blackwell Publishing Ltd</subfield><subfield code="c">1997</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zzz</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">z</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">nicht spezifiziert</subfield><subfield code="b">zu</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This study was performed in Corte de Pedra, an area of L. braziliensis braziliensis transmission located 240 km southeast of Salvador, the capital of the state of Bahia in Brazil. This open controlled trial included 34 patients, aged 12 to 45 years, with leishmania-positive skin test and a maximum of three ulcerated lesions (with a minimum lesion diameter of 10 mm and a maximum diameter of 50 mm) who had received no previous treatment. Exclusion criteria included chronic disease, use of other drugs, history of allergy to allopurinol, pregnancy, breast feeding, or forms of leishmaniasis other than cutaneous. Informed consent was obtained from all subjects after the nature of the procedures had been fully explained to them.Randomly selected patients received 20 mg/kg of allopurinol orally, three times a day, or 10 mg/kg of intravenous antimoniate of meglumine, once a day. Both patient groups used the drugs for a period of 20 days. A clinical history was collected and a physical examination was performed on all patients before initiating the treatment. Lesions were photographed and biopsied, and the tissue was used for histopathologic study and inoculation in hamsters and appropriate culture media. Patients were re-examined on days 10 and 20 and at monthly intervals for 1 year following the beginning of treatment. Blood samples for serologic and biochemical analysis (measurements of serum uric acid, urea, crsatinine, and transaminases) were collected at days 0, 10, and 22 following the beginning of treatment.The definition of therapeutic failure included incompletion of the treatment protocol, use of a treatment different from the protocol, lesions not healed 3 months after the beginning of treatment, or relapse or development of new cutaneous or mucosal lesions caused by leishmaniasis within 1 year of treatment.The exact Fischer test was used to compare the treatment results between the two patient groups. Student's t-test was used to compare the age of the patients and the duration of the illness. The Mann-Whitney test was used to compare the diameter of the lesions at day 0 and 3 months after treatment completion in the two groups, and the Kruskal-Wallis test was used to compare the number of lesions per patient and their localization.</subfield></datafield><datafield tag="533" ind1=" " ind2=" "><subfield code="d">2008</subfield><subfield code="f">Blackwell Publishing Journal Backfiles 1879-2005</subfield><subfield code="7">|2008||||||||||</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Machado, Paulo Roberto L.</subfield><subfield code="c">md</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Carvalho, Edgar M.</subfield><subfield code="c">md, phd</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">International journal of dermatology</subfield><subfield code="d">Oxford [u.a.] : Wiley-Blackwell, 1970</subfield><subfield code="g">36(1997), 12, Seite 0</subfield><subfield code="h">Online-Ressource</subfield><subfield code="w">(DE-627)NLEJ243927347</subfield><subfield code="w">(DE-600)2020365-2</subfield><subfield code="x">1365-4632</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:36</subfield><subfield code="g">year:1997</subfield><subfield code="g">number:12</subfield><subfield code="g">pages:0</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">http://dx.doi.org/10.1046/j.1365-4362.1997.00308.x</subfield><subfield code="q">text/html</subfield><subfield code="x">Verlag</subfield><subfield code="z">Deutschlandweit zugänglich</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_U</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">ZDB-1-DJB</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_NL_ARTICLE</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">36</subfield><subfield code="j">1997</subfield><subfield code="e">12</subfield><subfield code="h">0</subfield></datafield></record></collection>
|
| score |
7.400717 |